

joint procurement and joint negotiation authority.

Proposed Effective Date: 6/30/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/317>.

Agreement No.: 012390–001.

Agreement Name: Siem Car Carriers AS/Liberty Global Logistics LLC Space Charter Agreement.

Parties: Siem Car Carriers AS and Liberty Global Logistics LLC.

Filing Party: Ashley Craig; Venable LLP.

Synopsis: The amendment updates Article 5.3 of the Agreement to remove joint procurement and joint negotiation authority.

Proposed Effective Date: 6/30/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/1006>.

Agreement No.: 201363.

Agreement Name: Höegh Autoliners/National Shipping Company of Saudi Arabia (Bahri) Space Charter Agreement.

Parties: Hoegh Autoliners AS and The National Shipping Company of Saudi Arabia d.b.a. Bahri AS.

Filing Party: Wayne Rohde; Cozen O'Connor.

Synopsis: The Agreement authorizes the parties to charter space to/from one another in all U.S. trades worldwide.

Proposed Effective Date: 8/15/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/47520>.

Agreement No.: 201348–001.

Agreement Name: APL/Swire Guam, Saipan—S. Korea, Japan Slot Charter Agreement.

Parties: American President Lines, LLC and The China Navigation Co. Pte. Ltd. d/b/a Swire Shipping.

Filing Party: Patricia O'Neill; American President Lines, LLC.

Synopsis: The Amendment revises Article 5.1 to add Hakata, Japan as a port call under the Agreement.

Proposed Effective Date: 7/2/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/34502>.

Agreement No.: 012426–006.

Agreement Name: The OCEAN Alliance Agreement.

Parties: COSCO SHIPPING Lines Co., Ltd.; CMA CGM S.A. and APL Co. Pte. Ltd. (acting as a single party); Evergreen Marine Corporation (Taiwan) Ltd.; and Orient Overseas Container Line Limited.

Filing Party: Robert Magovern; Cozen O'Connor.

Synopsis: The Amendment revises Article 2 to add Evergreen Marine (Asia) Pte. Ltd. as a sub-party to the Agreement.

Proposed Effective Date: 8/20/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/1214>.

Agreement No.: 201351–001.

Agreement Name: Foundation Carrier Agreement.

Parties: Maersk A/S; CMA CGM S.A. MSC Mediterranean Shipping Company S.A.; Hapag-Lloyd AG; and Ocean Network Express Pte Ltd.

Filing Party: Wayne Rohde; Cozen O'Connor.

Synopsis: The amendment adds Hapag-Lloyd Aktiengesellschaft and Ocean Network Express Pte Ltd. as parties to the Agreement, and makes corresponding adjustments in Articles 5.1(b), 5.3(c), and 6.4 of the Agreement.

Proposed Effective Date: 8/21/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/36502>.

Agreement No.: 201364.

Agreement Name: Agreement Between the City of Los Angeles, the City of Long Beach, Portcheck, LLC, and Marine Terminal Operators.

Parties: Portcheck, LLC; The City of Long Beach Harbor Department; The City of Long Beach Harbor Department; APM Terminals Pacific LLC; Fenix Marine Services, Ltd.; Everport Terminal Services, Inc.; International Transportation Service, LLC; LBCT LLC; Total Terminals International, LLC; West Basin Container Terminal LLC; Pacific Maritime Services, LLC; SSAT (Pier A), LLC; Yusen Terminals LLC; Trapac LLC, and SSA Terminals, LLC.

Filing Party: Wayne Rohde; Cozen O'Connor.

Synopsis: The Agreement sets forth the terms and conditions under which PortCheck LLC and the marine terminal operators will provide certain services to the ports as provided for in tariffs published by the ports. These services relate to the collection of a clean truck fee in accordance with provisions to be published in the ports' respective tariffs.

Proposed Effective Date: 8/20/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/47525>.

Agreement No.: 012214–001.

Agreement Name: Glovis/"K" Line Space Charter Agreement.

Parties: Kawasaki Kisen Kaisha, Ltd. and Hyundai Glovis Co., Ltd.

Filing Party: John Meade, "K" Line America, Inc.

Synopsis: The amendment eliminates the parties' authority to jointly negotiate for covered services under the Agreement and updates the address for Hyundai Glovis.

Proposed Effective Date: 7/1/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/265>.

Agreement No.: 201365–002.

Agreement Name: Volkswagen Konzernlogistik GmbH & Co. OHG/NYK Line Space Charter Agreement.

Parties: Volkswagen Konzernlogistik GmbH & Co. OHG and Nippon Yusen Kaisha.

Filing Party: Kristen Chung; NYK Group Americas Inc.

Synopsis: The amendment removes all authority to jointly negotiate or procure terminal services in the United States.

Proposed Effective Date: 7/2/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/60>.

Agreement No.: 012386–001.

Agreement Name: K Line/NYK Space Charter Agreement.

Parties: Kawasaki Kisen Kaisha, Ltd. and Nippon Yusen Kaisha.

Filing Party: Kristen Chung; NYK Group Americas Inc.

Synopsis: This amendment removes all authority to jointly negotiate or procure terminal services in the United States.

Proposed Effective Date: 7/2/2021.

Location: <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/1002>.

Dated: July 8, 2021.

Rachel E. Dickon,

Secretary.

[FR Doc. 2021–14926 Filed 7–13–21; 8:45 am]

BILLING CODE 6730–02–P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors.

This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than August 13, 2021.

A. *Federal Reserve Bank of Boston* (Prabal Chakrabarti, Senior Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02210-2204. Comments can also be sent electronically to BOS.SRC.Applications.Comments@bos.frb.org:

1. *Independent Bank Corp.*, ("Independent") through its subsidiary, *Bradford Merger Sub Inc.*, both of *Rockland, Massachusetts*; to merge with *Meridian Bancorp, Inc.*, Peabody, Massachusetts ("Meridian"), with Meridian as the survivor, and thereby indirectly acquire East Boston Savings Bank, Boston, Massachusetts. Immediately after, Meridian to merge with Independent, with Independent as the survivor, and East Boston Savings Bank to merge with and into Rockland Trust, Rockland, Massachusetts, a wholly owned subsidiary bank of Independent, with Rockland Trust as the surviving bank.

Board of Governors of the Federal Reserve System, July 9, 2021.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2021-14997 Filed 7-13-21; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS-10341]

Agency Information Collection Activities: Submission for OMB Review; Comment Request

AGENCY: Centers for Medicare & Medicaid Services, HHS.

ACTION: Notice; partial withdrawal.

SUMMARY: On Friday, July 9, 2021, the Centers for Medicare & Medicaid Services (CMS) published a notice

entitled, "Agency Information Collection Activities: Submission for OMB Review; Comment Request." That notice invited public comments on three separate information collection requests specific to document identifiers: CMS-10215, CMS-10249, and CMS-10341. Through the publication of this document, we are withdrawing the portion of the notice requesting public comment on the information collection request titled "Section 1115 Demonstration Projects Regulations at 42 CFR 431.408, 431.412, 431.420, 431.424, and 431.428." Form number CMS-10341 (OMB control number 0938-1162). The withdrawn information collection request will be replaced by another 30-day notice in July or August of this year.

DATES: For CMS-10215 and CMS-10249, the original comment period for the notice that published on July 9, 2021, remains in effect and ends August 9, 2021.

SUPPLEMENTARY INFORMATION: In FR document, 2021-14671, published on July 9, 2021 (86 FR 36281), we are withdrawing item 3 "Section 1115 Demonstration Projects Regulations at 42 CFR 431.408, 431.412, 431.420, 431.424, and 431.428" which posted on page 36282.

Dated: July 9, 2021.

William N. Parham, III,

Director, Paperwork Reduction Staff, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2021-15005 Filed 7-13-21; 8:45 am]

BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-P-0191]

Determination That STROMEKTOL (Ivermectin) Tablets, 6 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that STROMEKTOL (ivermectin) tablets, 6 milligrams (mg), were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for STROMEKTOL (ivermectin) tablets, 6

mg, if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Christopher Koepke, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-3600, Christopher.Koepke@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments), which authorized the approval of duplicate versions of drug products under an ANDA procedure. ANDA applicants must, with certain exceptions, show that the drug for which they are seeking approval contains the same active ingredient in the same strength and dosage form as the "listed drug," which is a version of the drug that was previously approved. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

The 1984 amendments include what is now section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the "Approved Drug Products With Therapeutic Equivalence Evaluations," which is known generally as the "Orange Book." Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug's NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

STROMEKTOL (ivermectin) tablets, 6 mg, are the subject of NDA 050742, held by Merck Sharp and Dohme Corp., and initially approved on November 22, 1996. STROMEKTOL is indicated for strongyloidiasis of the intestinal tract and onchocerciasis.

In a letter dated September 14, 2007, Merck and Co., Inc. notified FDA that STROMEKTOL (ivermectin) tablets, 6 mg, were being discontinued, and FDA